Samuel Cytryn, MD, discusses two major recent developments in gastric and gastroesophageal cancer research: the DESTINY-Gastric04 and MATTERHORN trials. DESTINY-Gastric04 is a global phase III study comparing trastuzumab deruxtecan with ramucirumab and paclitaxel in the second-line setting, demonstrating promising survival benefits. The MATTERHORN trial evaluates the addition of durvalumab to perioperative FLOT chemotherapy for locally advanced gastric or gastroesophageal cancer, with early results indicating an improvement in event-free survival.
GI Oncology Now
The leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies
Latest News
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
The approval is based on positive results from the phase III RATIONALE-306 study.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
Patients with refractory UGI cancers who participated in phase I trials saw benefits in late-line settings.
Conference Coverage
GI Oncology Now reviews education from ASCO GI 2025, featuring the latest advances in the field of GI cancer research.
Coverage of the 2025 ASCO GI Symposium, with a focus on liver cancer
The latest news and research updates in GI cancer treatment from the ESMO Congress 2024
The latest news and research updates in GI cancer treatment from the ASCO 2024 Annual Meeting
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Editorial Advisory Board
Christopher Lieu, MDEditor | Co-Director of Gastrointestinal Medical Oncology at University of Colorado Medicine
Benjamin Weinberg, MD, FACPEditor | Associate Professor of Medicine at Lombardi Comprehensive Cancer Center
Zev Wainberg, MD, MScEditor | Co-Director of Gastrointestinal Oncology at the University of California, Los Angeles
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.